FDA
-
-
-
-
-
-
-
Galmed CEO outlines drug development plans in shareholder letter
-
-
-
-
-
-
-
Galmed plans to invest up to $10 million in digital assets
-
-
-
-
-
-
-
Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers
-
-
-
-
-
-
-
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
-
-
-
-
-
-
-
Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study
-
-
-
-
-
-
-
Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments
-
-
-
-
-
-
-
Galmed Pharma (GLMD) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

